Core Insights - The article discusses the growing attention on synthetic lethality as a precise treatment strategy in cancer therapy, targeting tumor-specific gene dependencies to overcome treatment resistance and "undruggable" targets [1][2]. Group 1: Synthetic Lethality Mechanism - Synthetic lethality is based on specific gene combinations where the inactivation of either gene alone does not affect cell viability, but simultaneous inactivation leads to cell death [2][16]. - A classic example of synthetic lethality is the use of PARP inhibitors, which target cancer cells with BRCA1 or BRCA2 mutations, leading to cell death due to the inability to repair DNA damage [3][18]. - Since the approval of the first PARP inhibitor, olaparib, in 2014, several others have emerged, showing efficacy in ovarian, breast, prostate, and pancreatic cancers [19]. Group 2: New Combinations and Research - The success of PARP inhibitors has encouraged further exploration of other "golden combinations" in synthetic lethality, such as MSI-WRN in colorectal and endometrial cancers, where inhibiting WRN can selectively kill cancer cells [4][20]. - Another promising combination is MTAP-PRMT5, where the loss of MTAP in melanoma and mesothelioma leads to a dependency on PRMT5, with inhibitors currently in clinical trials [6][22]. - Over 30 candidate drugs based on synthetic lethality mechanisms are currently in clinical development, focusing on key pathways like DNA damage repair, RNA splicing, and cell cycle regulation [6][22]. Group 3: Challenges in Development - Despite the potential of synthetic lethality, challenges remain in translating laboratory findings into effective drugs for patients, particularly due to the complexity of gene interactions [7][23]. - Many synthetic lethality combinations involve homologous genes, which can lead to toxicity when targeting similar genes, necessitating precise drug design [10][25]. - The applicability of identified synthetic lethality combinations can vary across different cancer types, requiring ongoing research to validate and assess their effectiveness [10][25]. Group 4: WuXi Biology's Role - WuXi Biology provides comprehensive biological services and solutions to support the early development of synthetic lethality drugs, from target discovery to candidate screening and clinical trials [11][26]. - The platform offers various in vitro testing tools and has established nearly 40 animal models related to BRCA deficiencies, covering multiple cancer types for in vivo research [12][27]. - WuXi Biology has developed around 50 animal models for PRMT5 and WRN pathways, supporting the development and evaluation of new synthetic lethality therapies [14][29].